Société Internationale d’Urologie Journal

Background/Objectives: Robotic-assisted simple prostatectomy (RASP) is an increasingly popular surgical approach for prostate enucleation. The aim of this study is to evaluate the incidence of perioperative and delayed complications following RASP and the medium- to long-term urinary function outcomes. Methods: This is a multi-centre retrospective chart analysis of patients who underwent RASP between October 2016 and October 2022. Surgery was performed using a transvesical approach with a DaVinci Xi system. Patients were reviewed pre- and postoperatively at six weeks and annually thereafter. Patient characteristics, perioperative outcomes, pre- and postoperative uroflowmetry and post-void residual (PVR) measurement were assessed. Results: A total of 50 patients with mean preoperative prostate volume of 180.3 ± 48.1 underwent RASP. The mean operative time was 140.7 ± 28.7 min and hospital length of stay was 5.2 ± 2.9 days. The mean intraoperative blood loss was 247.4 ± 153.7 mL and no patients required transfusion. The mean follow-up period was 37.2 ± 18.3 months. No patients developed stress urinary incontinence. Two patients developed delayed bladder neck contracture at 44 and 63 months. There was a significant improvement in peak urinary flow rate (Qmax) (preop Qmax 10.7 mL/s vs. postop Qmax 24.2 mL/s, p < 0.05) and PVR (preop PVR 366.5 mL vs. postop PVR 42.2 mL, p < 0.05). All patients were weaned off medical therapy for benign prostatic enlargement (BPE) and no patients had recurrent lower urinary tract symptoms requiring re-operation. Conclusions: RASP is a safe and effective enucleation technique for large prostates >100 mL with excellent long-term durability of urinary function outcomes beyond 36 months.

Several liquid-, and tissue-based markers are available to guide primary diagnosis-, active surveillance-, and treatment-related decision-making for patients with prostate cancer. Most of these tests can improve the balance of harms and benefits associated with early detection, and aid patient selection for treatment intensification. However, the costs of these tests can make their integration in routine clinical practice challenging. To date, prostate-specific antigen (PSA) is still one of the most well-known and widely utilized tumor markers worldwide, with a unique facility ranging from the diagnosis to the treatment-related follow-up of patients with prostate cancer. Future research efforts are needed to integrate biomarkers and novel imaging techniques, such as prostate magnetic resonance imaging, in the decision-making pathways. Despite the growing body of knowledge and evidence, considerable challenges remain in optimizing risk-stratification, improving patient selection and cost-efficacy in different prostate cancer (PCa)-related settings.

The SIU wishes to extend its gratitude to the urologists who contributed their time to review abstract submissions for the 45th SIU Congress:Refaat Abusamra, Libya;Sanjai Addla, India;Kinju Adhikari, India;Neeraj Agarwal, United States;Madhu Agrawal, India;Sachin Agrawal, United Kingdom;Thomas Ahlering, United States;Shusuke Akamatsu, Japan;Peter Albers, Germany;Salah Albuheissi, United Kingdom;Naif Alhathal, Saudi Arabia;Bedeir Ali-El-Dein, Egypt;Murtadha Almusafer, Iraq;Anastasios Anastasiadis, Greece;Mohamed Arafa, Qatar;Amandeep Arora, India;Zeeshan Aslam, United Kingdom;Hammad Ather, Pakistan;Widi Atmoko, Indonesia;Melanie Aubé-Peterkin, QC;Riccardo Autorino, United States;Ben Ayres, United Kingdom;Puskal Kumar Bagchi, India;Ganesh Bakshi, India;Mevlana Derya Balbay, Turkey;Neil Barber, United Kingdom;John Barry, United States;Jens Bedke, Germany;Elisa Berdondini, Italy;Gajanan Bhat, India;Amit Bhattu, United States;Naeem Bhojani, Canada;N I Bhuiyan, Bangladesh;Marta Bizic, Serbia;Damien Bolton, Australia;Vincenzo Borgna, Chile;Muhammad Bulbul, Lebanon;Gian Maria Busetto, Italy;Ana Gabriela Caballero Garcia, Mexico;Adam Calaway, United States;Amparo Camacho, United States;Kevin Campbell, United States;Francesco Capelan, Switzerland;Manuel Castanheira de Oliveira, Portugal;Christine Joy Castillo, Philippines;David Castro-Diaz, Spain;Arun Chawla, India;Manohar ChikkaMoga Siddaiah, India;Archil Chkhotua, Georgia;Sung Yong Cho, Korea, Rep [...]